Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
Status:
Completed
Trial end date:
2013-08-24
Target enrollment:
Participant gender:
Summary
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major
depressive disorder patients with lack of response to existing antidepressants, with the aim
of evaluating the efficacy of quetiapine XR and dose-response in three quetiapine XR dose
groups based on changes in Montgomery-Asberg Depression Rating Scale (MADRS) scores.